Exosome diagnostic assays

Thermo Fisher Scientific, Qiagen, Bio-Techne and Exosome Diagnostics are prominent companies in this field. Thermo Fisher Scientific provides exosome isolation and characterization tools, while Qiagen supplies sample-preparation technologies relevant to exosomal RNA. Bio-Techne offers the ExoDx Prostate test through its Exosome Diagnostics business; it analyzes urinary exosomal RNA to help inform prostate-biopsy decisions.

Exopert Corporation is the startup listed in FACTS, with 4 documents in the 24-month window. Its associated research investigates exosome spectral profiling and an SERS–AI platform for cancer diagnosis. This supports describing its technical direction, but the available facts do not establish clinical validation, commercial readiness or comparative performance against other assay developers.

Fudan University, Southern Medical University and the University of Sichuan are among the leading research organizations in FACTS, with 70, 77 and 60 documents in the 24-month window, respectively. Their work includes electrochemical exosome assays, multiplex profiling of breast-cancer exosome subtypes and magnetic aptasensing. The figures indicate activity in the topic, not a ranking of research quality.

FACTS records $7,190,991 across 24 grants since 2020. The funding data does not identify a specific public program as the source of those grants, and the listed institutional funding rounds cannot be reliably attributed to assay development. Treat the grant total as the recorded funding signal rather than a complete measure of investment in the field.

Lonza Sales Ltd and Zhejiang Synsorbio Technology Co. have the highest counts in the listed patent-holder data, with 3 patents each. Solbio SA, Listen Technologies, Korea University Research And Business Foundation, The Clinic by Cleveland Clinic, Ono Pharmaceutical Co., Ltd. and Corramedical, Inc. each have 2. These counts describe the patent holders shown in FACTS.

Patent activity is lower in the reported comparison: FACTS lists 96 patents in the 24-month window and a growth figure of -42.6%. By contrast, publications in the last year numbered 2,309, with publication growth of 17.9%. The differing direction suggests research output is expanding while patenting activity, as measured here, is contracting.

Recent developments include Guizhou Medical University’s dual-aptamer RCA-MOF colorimetric assay for leukemia-derived exosomes in September 2026 and a dual-marker electrochemical prostate-cancer assay from Fudan University and Xuzhou Medical University in August 2026. Southern Medical University also reported droplet-microarray profiling of breast-cancer exosome subtypes. These examples point to visual, electrochemical and multiplex analysis.

The main approaches are nucleic-acid cargo assays, protein biomarker assays, vesicle isolation and enrichment, single-vesicle detection, and integrated sensing platforms. RNA and protein assays target different molecular signals; isolation prepares vesicles for analysis, while single-vesicle methods resolve heterogeneity. Integrated platforms combine steps, potentially simplifying workflows but requiring careful validation of the full assay.

Cancer detection and monitoring is the largest listed application, with 1,670 documents in FACTS. Other applications include neurological disease, infectious disease, cardiovascular disease and veterinary diagnostics, with 766, 591, 236 and 47 documents, respectively. Research examples include prostate, breast, lung and ovarian cancer assays, as well as studies of exosomal markers in neurological conditions.

The United States leads the country data with 8,521 documents, followed by China with 7,172. The United Kingdom has 4,211, India 4,113 and Germany 4,047. These figures represent documents associated with each country in FACTS; they indicate research and innovation activity rather than the location of commercial assay sales or clinical adoption.